Ahmedabad-based pharma major Cadila Healthcare (Zydus Cadila) on Thursday launched a migraine drug in the US market uponreceiving the final approval from the USFDA. The company announced the Day 1 launch of Zolmitriptan orally disintegrating tablets here on Thursday. It will be marketed in the strengths of 2.5 mg and 5 mg in the US market.
The group now has 79 approvals and has so far filed 173 ANDAs since the commencement of the filing process in 2003-04.
Meanwhile, Zydus Wellness Ltd, a personal care company under the umbrella of Cadila Healthcare Ltd, posted a 59.2 per cent jump in net profit during the fourth quarter of the fiscal ending March 31, 2013 to Rs 37.4 crore on the back of higher sales.
The company's gross sales during the quarter stood at Rs 108.4 crore, up 26.3 per cent from Rs 85.8 crore in the corresponding quarter last year on a consolidated basis.
For the year ended March 31, 2013, Zydus Wellness registered a 19 per cent rise in consolidated gross sales to Rs 410 crore, according to a company release here.
Net profit for the year was up by 43.5 per cent to Rs 97.1 crore as against Rs 67.7 crore during 2011-12.
